Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Keir ST, Maris JM, Billups CA, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2013 May;60(5):791-8. doi: 10.1002/pbc.24301. Epub 2012 Sep 21.

2.

The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.

Foster P, Yamaguchi K, Hsu PP, Qian F, Du X, Wu J, Won KA, Yu P, Jaeger CT, Zhang W, Marlowe CK, Keast P, Abulafia W, Chen J, Young J, Plonowski A, Yakes FM, Chu F, Engell K, Bentzien F, Lam ST, Dale S, Yturralde O, Matthews DJ, Lamb P, Laird AD.

Mol Cancer Ther. 2015 Apr;14(4):931-40. doi: 10.1158/1535-7163.MCT-14-0833. Epub 2015 Jan 30.

3.

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ.

Pediatr Blood Cancer. 2010 Jul 15;55(1):26-34. doi: 10.1002/pbc.22430.

4.

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.

Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH, Watkins A, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2010 Dec 1;55(6):1126-33. doi: 10.1002/pbc.22712.

5.

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2014 Jan;61(1):158-64. doi: 10.1002/pbc.24616. Epub 2013 Aug 19.

6.

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.

Carol H, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ, Lock RB.

Pediatr Blood Cancer. 2010 Dec 15;55(7):1329-37. doi: 10.1002/pbc.22710. Epub 2010 Aug 25.

7.

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, Houghton PJ.

Pediatr Blood Cancer. 2012 Aug;59(2):246-53. doi: 10.1002/pbc.23357. Epub 2011 Oct 19. Erratum in: Pediatr Blood Cancer. 2012 Oct;59(4):772.

8.

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.

Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA.

Pediatr Blood Cancer. 2008 Mar;50(3):581-7.

PMID:
17457854
9.

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.

Houghton PJ, Kurmasheva RT, Lyalin D, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Smith MA.

Pediatr Blood Cancer. 2014 Nov;61(11):1972-9. doi: 10.1002/pbc.25175. Epub 2014 Aug 17.

10.

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ.

Pediatr Blood Cancer. 2011 Apr;56(4):595-603. doi: 10.1002/pbc.22741. Epub 2010 Dec 22.

11.

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.

Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Phelps D, Maris JM, Billups C, Smith MA.

Pediatr Blood Cancer. 2012 Feb;58(2):191-9. doi: 10.1002/pbc.22935. Epub 2011 Feb 18.

12.

Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.

Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Wu J, Smith MA.

Pediatr Blood Cancer. 2008 Jun;50(6):1181-9.

PMID:
18085673
13.

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.

Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MA.

Pediatr Blood Cancer. 2012 Oct;59(4):749-52. doi: 10.1002/pbc.23364. Epub 2011 Nov 2.

14.

Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.

Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MA.

Pediatr Blood Cancer. 2012 Sep;59(3):518-24. doi: 10.1002/pbc.23412. Epub 2011 Nov 18.

15.

Initial testing of dasatinib by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA.

Pediatr Blood Cancer. 2008 Jun;50(6):1198-206.

PMID:
17914733
16.

Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.

Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB.

Pediatr Blood Cancer. 2013 Apr;60(4):633-41. doi: 10.1002/pbc.24235. Epub 2012 Jul 2.

17.

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program.

Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Reynolds CP, Kang MH, Billups CA, Collins J, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2016 Mar;63(3):443-50. doi: 10.1002/pbc.25826. Epub 2015 Nov 24.

PMID:
26797892
18.

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.

Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock R.

Pediatr Blood Cancer. 2014 Feb;61(2):245-52. doi: 10.1002/pbc.24724. Epub 2013 Sep 4.

19.

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program.

Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Billups CA, Smith MA.

Pediatr Blood Cancer. 2012 Apr;58(4):636-9. doi: 10.1002/pbc.23167. Epub 2011 Jun 16.

20.

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2013 Aug;60(8):1325-32. doi: 10.1002/pbc.24517. Epub 2013 Mar 28.

Items per page

Supplemental Content

Write to the Help Desk